Thompson, G. R. Et Al. 2023. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.. Lancet (London, England) , vol.401, no.10370 , 49-59.

Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., ... Honore, P. M.(2023). Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.. Lancet (London, England) , vol.401, no.10370, 49-59.

Thompson, George Et Al. "Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.," Lancet (London, England) , vol.401, no.10370, 49-59, 2023

Thompson, George R. Et Al. "Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.." Lancet (London, England) , vol.401, no.10370, pp.49-59, 2023

Thompson, G. R. Et Al. (2023) . "Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.." Lancet (London, England) , vol.401, no.10370, pp.49-59.

@article{article, author={George R Thompson Et Al. }, title={Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.}, journal={Lancet (London, England)}, year=2023, pages={49-59} }